Compare MRNA & AU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRNA | AU |
|---|---|---|
| Founded | 2010 | 1944 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 49.5B |
| IPO Year | 2018 | 2023 |
| Metric | MRNA | AU |
|---|---|---|
| Price | $198.47 | $93.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $34.27 | ★ $119.00 |
| AVG Volume (30 Days) | ★ 13.5M | 1.7M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 3.94% |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $9.36 | $38.71 |
| Revenue Next Year | $15.43 | $2.89 |
| P/E Ratio | ★ N/A | $23.93 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $62.55 |
| 52 Week High | $202.67 | $129.14 |
| Indicator | MRNA | AU |
|---|---|---|
| Relative Strength Index (RSI) | 75.87 | 37.65 |
| Support Level | $43.35 | $89.75 |
| Resistance Level | N/A | $98.06 |
| Average True Range (ATR) | 11.47 | 2.66 |
| MACD | 2.59 | -1.65 |
| Stochastic Oscillator | 86.71 | 13.20 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Anglogold Ashanti PLC is an independent gold mining company. It has a diversified asset portfolio, including production from operations in eight countries (Argentina, Australia, Brazil, Egypt, Ghana, Guinea, the DRC, and Tanzania), supported by greenfield projects in the United States and Colombia. The company's main product is gold, which once mined, is processed into dore (unrefined gold bars) on site and then dispatched to precious metals refineries. Geographically, Anglogold generates maximum revenue from its operations in Africa (comprising operations at Kibali, Iduapriem, Obuasi, Siguiri, Geita, and Sukari mines), followed by Australia (including Sunrise Dam and Tropicana), and the Americas (comprising Cerro Vanguardia, AngloGold Ashanti Mineracao, and Serra Grande operations).